Literature DB >> 3166545

The use of doxycycline in nervous system Borrelia burgdorferi infection.

L Dotevall1, K Alestig, P Hanner, G Norkrans, L Hagberg.   

Abstract

Alternatives to high dose benzylpenicillin treatment are sought for in patients with mild Borrelia burgdorferi nervous system infection. Doxycycline 100 mg twice daily for 10-20 days was used in nine patients with radicular pains, vertigo or weakness in the legs caused by B. burgdorferi infection. The patients had suffered from neurologic symptoms for a median time of five months. In eight patients doxycycline was orally administered and in one intravenously. All nine patients had remission of radicular pain and vertigo during the treatment period. Two patients with weakness in the legs improved slowly in muscle strength over a three month period. The doxycycline concentration in the cerebrospinal fluid was 0.2-1.0 mg/l and in serum 1.9-7.1 mg/l after five days treatment. Doxycycline treatment was found successful in our patients with mild tick borne neuroborreliosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166545

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  7 in total

1.  Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis.

Authors:  M Karlsson; S Hammers; I Nilsson-Ehle; A S Malmborg; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis.

Authors:  L Dotevall; L Hagberg
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 3.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Doxycycline versus ceftriaxone for the treatment of patients with chronic Lyme borreliosis.

Authors:  Katarina Ogrinc; Mateja Logar; Stanka Lotric-Furlan; Dasa Cerar; Eva Ruzić-Sabljić; Franc Strle
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

Review 5.  Current recommendations for the treatment of Lyme disease.

Authors:  L H Sigal
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

6.  Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.

Authors:  F Strle; V Preac-Mursic; J Cimperman; E Ruzic; V Maraspin; M Jereb
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

7.  High-dose intravenous penicillin G does not prevent further progression in early neurological manifestation of Lyme borreliosis.

Authors:  J Kohler; H Schneider; A Vogt
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.